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The American Heart Association liberalised guidelines for carotid stenting (CAS) into average risk
patients based on the following interpretations and assumptions; (i) CAS doubles the risk of procedural
stroke; (ii) CEA doubles the risk of procedural myocardial infarction (MI); (iii) peri-operative MI signif-
icantly reduces long-term survival; (iv) poorer long-term survival is attributable to a greater proportion
of CEA patients dying after their peri-operative MI. (v) reduced survival in CEA patients suffering a peri-
operative MI offsets any beneﬁt conferred by the lower procedural stroke risk so that; (vi) CAS is
considered equivalent to CEA and may even be safer in those considered high risk for procedural MI.
However, this much publicised rationale is ﬂawed by the simple fact that the poorer survival rates
observed in CREST were not attributable to a greater proportion of CEA patients dying following their
procedural MI. In fact, a relatively higher proportion of CAS patients suffering a peri-operative MI died
during follow-up.
This observation changes how the literature should be interpreted. The clinical reality is that up to 10%
of patients will suffer a stroke within seven days of their index TIA and the beneﬁts of intervening in the
hyperacute period after onset of symptoms (ie offering greater stroke prevention) will far outweigh any
potential consequences of peri-operative MI and reduced life expectancy. Peri-operative MI should
inform, but not drive the current debate. More importantly, it should not deﬂect attention away from the
most important management priority; the prevention of stroke. This is one situation where the heart
should not rule the head!
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.“When the heart speaks, the mind ﬁnds it indecent to object”
Milan Kundera
Evidence suggests that after a successful carotid stent (CAS)
procedure, the long-term risk of ipsilateral stroke is probably no
different to that following carotid endarterectomy (CEA).1 As
a consequence, the magnitude of the procedural risk will largely
determine howguidelines evolve. If both interventions have similar
risks, there is a strong case for accepting a liberalisation of CAS
indications.
But what is meant by ‘risk’? The traditional endpoint is 30-day
death/stroke and 15 meta-analyses of the randomised trials have
observed that stenting is associated with a two-fold excess risk of
death/stroke compared with CEA. Even when historical studies are
excluded, there is still a doubling of stroke/death following CAS2
and the same holds true if one only looks at outcomes in symp-
tomatic patients who were randomised within CREST (30-day
death/stroke 6.0% versus 3.2% after CEA (HR 1.9 (95%CI 1.1e3.2),ciety for Vascular Surgery. Publishep ¼ 0.02).3 As a consequence, recommendations published prior to
2011 generally advise that CEA should remain the ﬁrst-line inter-
vention for ‘average risk’ symptomatic and asymptomatic patients.4
However, advocates of stenting have argued that ‘risk’ should
not be limited to death/stroke5 and should include peri-operative
myocardial infarction (MI) (including biomarker þve MI in the
absence of chest pain or ECG changes) because both are associated
with poorer long-term survival.6 Accordingly, the rationale for
according MI the same status as death or stroke is that even if CEA
were associated with a signiﬁcantly lower procedural stroke risk
(compared with CAS), this is likely to be offset by a higher rate of
peri-operative MI and reduced long-term survival.5
Some Surgeons (and Neurologists) were not particularly happy
that CREST accorded MI the same status as death and stroke,7,8 but
anyone reviewing the literature has to concede that (at ﬁrst sight)
vascular surgery patients who suffer a peri-operative MI do seem to
have poorer long-term survival.6 In 2002, Kim observed that
elevated levels of cardiac Troponin I (CTI) in the early post-
operative period were associated with a six-fold increase in
mortality at six months.9 In a similar project involving 447 vascular
surgery patients, an elevated creatine kinase MB fraction in the
post-operative period was associated with a four-fold increase ind by Elsevier Ltd. All rights reserved.
Table 2
Peri-operative MI and late mortality in CREST.a
Adjudicated MI Biomarker þve
MI
‘Any MI’
n died (%) n died (%) n died (%)
CEA 28 5 (18%) 12 2 (17%) 40 7 (18%)
CAS 14 3 (21%) 8 3 (38%) 22 6 (27%)
Adjudicated MI ¼ biomarker elevation plus either chest pain or ECG evidence of
ischaemia BiomarkerþveMI¼ biomarker elevation with neither chest pain nor ECG
abnormality.
a Data derived from Blackshear et al.12
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increase in late mortality.10 As with Kim’s series, higher quartile
levels of CTI were associated with higher mortality rates during
follow-up.10
Table 1 details 30-day death/stroke and death/stroke/MI within
CREST.3,11 Death/stroke was twice as high in patients randomised to
CAS, but when MI (including biomarker þve MI) was included;
there was no signiﬁcant difference.11 In a second publication
(which seemed to corroborate the ﬁndings of Kim9 and Land-
esberg10), CREST observed that patients suffering an adjudicated MI
(biomarker elevation plus chest pain or ECG changes) faced
a threefold increase in late mortality (HR 3.4 (95%CI 1.7e6.0),
p ¼ 0.001), whilst patients with biomarker elevation alone faced
a near four-fold increase in late death (HR 3.6 (95%CI 1.5e8.7),
p ¼ 0.023).12 CREST3 concluded that peri-operative MI was “inde-
pendently associated with increased future mortality and remained an
important consideration in choosing the mode of carotid revascular-
isation or medical therapy”. Others simply concluded that CREST had
clearly vindicated the decision to include MI within the composite
endpoint.5
Accordingly; guidelines published in 2011 that were based on
the premise that stroke prevention should remain the key deter-
minant of practice were more likely to recommend CEA as the ﬁrst-
line treatment in ‘average risk’ patients,13 whilst guidelines which
accepted peri-operative MI as being of equivalent status to death/
stroke were more likely to conclude that CEA and CAS had similar
procedural risks and that either modality could be considered in
‘average risk’ patients.14,15
Given the status accorded to American Heart Association
Guidelines, the inclusion of peri-operative MI has assumed
considerable importance in determining practice (sometimes over-
riding almost everything else). Despite CREST stating that “it was
premature to speculate whether these data should be used to guide
selection for CAS versus CEA”,12 the current vox populi interpretation
of the literature seems to be that; (i) CEA is associated with
a doubling of the risk of peri-operative MI; (ii) peri-operative MI is
associated with poorer long-term survival; (iii) the poorer long-
term survival is largely attributable to a greater proportion of MI
patients dying following CEA and that (iv) CAS may, therefore, be
the preferred intervention in anyone considered to be at increased
risk of procedural MI.
CREST showed that the only independent predictive factor for
procedural MI was a prior history of cardiovascular disease (ie MI,
angina, intermittent claudication or cardiac failure).12 Thus,
because cardiovascular disease is common in patients with symp-
tomatic and asymptomatic carotid disease, a large proportion of
patients might be advised to undergo CAS on the basis that they
were less likely to suffer a procedural MI and so live longer.
However, if one actually reads the CRESTMI paper more critically, it
soon becomes apparent that the vox populi interpretation of the
literature is ﬂawed.
The literature shows that; (i) peri-operative MI was signiﬁcantly
more common following CEA3 (although only 1/2502 CRESTTable 1
30-day procedural risks in the CREST trial; stratiﬁed for symptom status.a
30-Day death/stroke
CAS CEA HR (95% CI)
OVERALL 4.4% 2.3% 1.9 (1.2e3.0)
SYMPTOMATIC 6.0% 3.2% 1.9 (1.1e3.2)
ASYMPTOMATIC 2.5% 1.4% 1.9 (0.8e4.4)
HR ¼ Hazard Ratio; CAS ¼ carotid artery stenting, CEA ¼ carotid endarterectomy; CI ¼ C
a data derived from CREST.3,11patients (0.03%) died in the peri-operative period following fatal
MI3) and that (ii) peri-operative MI was associated with a 3e4 fold
increase in ‘any cause’ death. To-date, however, no information has
been provided about the causes of the late deaths (cardiovascular,
cancer, peripheral vascular disease etc). What has been overlooked,
however, is the fact that the poorer long-term survival was not
attributable to a greater proportion of CEA patients dying following
their procedural MI.
Table 2 details the prevalence and type of peri-operative MI in
CREST (adjudicated or biomarker þve) along with late mortality
(median follow-up 2.5 years). These data show that 7/40 CEA
patients (18%) who suffered a procedural MI died during the course
of follow-up, compared with 6/22 (27%) who suffered an MI after
CAS.12 Accordingly, it would be totally wrong to promote the
impression that the excess mortality in patients suffering a proce-
dural MI was largely attributable to deaths after CEA. In this rela-
tively small cohort of patients, a greater proportion of late deaths
were actually observed in CAS patients who suffered a peri-
operative MI.12 It might, therefore, be that the main message
from the CREST MI study was that better case selection (or better
peri-operative medical therapy) was required, as patients with
a history of cardiovascular disease were probably pre-destined to
have a poorer prognosis irrespective of whether they underwent
CEA or CAS.
These ﬁndings put a totally different slant on how the literature
should be interpreted, particularly as CREST was singularly inﬂu-
ential in driving the AHA14 to expand CAS indications into ‘average
risk’ patients. When determining practice in symptomatic patients,
the risk of peri-operative MI should not be the key consideration.
The single most important issue is rapid treatment (ie deciding
whether CEA or CAS is safer in the ﬁrst few days after onset of
symptoms16), as a greater proportion of patients will die or suffer
permanent disability through delayed interventions, compared to
a much lower likelihood of reduced life-expectancy following peri-
operative MI. Only 62/2502 patients (2.5%) suffered a peri-
operative MI in CREST and only 13 of these patients died during
a median follow-up of 2.5 years. Taken to its logical conclusion, this
means thatmajor changes in thewaywe nowmanage ‘average risk’
patients are being based on reduced life-expectancy in 13/2502
patients (0.5%) randomisedwithin CREST. It is a salutary fact that up30-Day death/stroke/MI
p CAS CEA HR (95% CI) p
0.005 5.2% 4.5% 1.2 (0.8e1.4) 0.38
0.02 6.7% 5.4% 1.3 (0.8e2.0) 0.30
0.15 3.5% 3.6% 1.0 (0.6e1.9) 0.96
onﬁdence Intervals.
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index TIA,17 perhaps even higher in patients with an ipsilateral
severe stenosis.18 The clinical reality, therefore, is that reducing the
prevalence of stroke in the hyperacute period after onset of
symptoms far outweighs any potential consequences of peri-
operative MI and reduced life-expectancy.
In addition, because many asymptomatic patients present with
a history of cardiovascular disease, it may be that a greater
proportion should now be treated medically (rather than by CEA or
CAS). Notwithstanding the potential for reduced life-expectancy
should anyone suffer a procedural MI, there is increasing
evidence that the natural history risk of stroke is declining in
patients with asymptomatic carotid disease.19 Rather than being
preferentially considered for CAS (which seems to be the current
message), most of these patients should probably be treated
conservatively.
There is, however, one other really important message arising
from this debate. If the Surgeon/Interventionist believes (after full
and thorough case review) that CEA or CAS is the most appropriate
intervention, he/she should also be vigilant in prescribing high
quality medical therapy both during the peri-operative period and
into the long term. This is especially important in patients with
a history of cardiovascular disease. Aspirin should not be stopped
and peri-operative dual antiplatelet therapy (routine in CAS
procedures) should be considered in patients undergoing CEA.20
Long-term statin therapy should not be stopped (there is evidence
that this may predispose to acute coronary plaque destabilisa-
tion21), whilst a meta-analysis of 300,000 patients suffering an
acute MI showed that commencing statin therapy within 24 h of
onset of symptoms signiﬁcantly reduced early complications and in-
hospital mortality.22 The inference from the latter study being that
patients under consideration for CEA or CAS in the emergency
setting will still beneﬁt from starting statin therapy <24 h of the
plannedprocedure, aswell as also enjoying the beneﬁts conferred in
reducing cardiovascular events in the long term.
In summary; concerns about peri-operative MI should certainly
inform, but not drive the debate as to whether CEA or CAS is
preferable in ‘average risk’ patients. Unfortunately the subject has
now assumed a level of inﬂuence that is not justiﬁed on the basis of
evidence. The choice of intervention will inevitably depend upon
a number of factors, most notably the need to intervene early.
However, the CREST MI study has not shown that the risk of peri-
operative MI should deﬂect attention away from the most impor-
tant priority; the prevention of stroke. This is one situation where
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